ARD podcast
We retired this podcast, because we couldn't parse it for 10 consecutive times.
- Website
- http://soundcloud.com/bmjpodcasts/sets/ard-podcast
- Description
- Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
- Language
- 🇬🇧 English
- last modified
- 2022-07-15 22:56
- last episode published
- 2022-02-07 21:50
- publication frequency
- 92.55 days
- Contributors
- BMJ Group
- Owner Author
- Explicit
- false
- Number of Episodes
- 31
- Rss-Feeds
- Detail page
- Categories
- Medicine Science & Medicine Health & Fitness
Recommendations
Episodes
| Date | Title & Description | Contributors |
|---|---|---|
| 2022-02-07 |
Innate Lymphoid Cells link TGFb and fibrotic pathways in systemic sclerosis skin In this podcast, Dr. Truchetet discusses her work on the role of innate lymphoid cells in the fibrotic processes in systemic sclerosis (SSc) patients. The group of Dr. Truchetet found that ILC2 are crucial mediators of skin fibrosis in SSc and that com... |
|
| 2021-07-29 |
Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD'... |
|
| 2021-03-18 |
The EULAR COVID-19 database and its insights into risk factors The EULAR COVID-19 database and the COVID-19 Global Rheumatology Alliance work together on shared collected data to address the most pertinent questions in regard to risks for people with rheumatic diseases and COVID-19 infection. The latest study conf... |
|
| 2020-09-15 | Capturing disease progression in SSc is challenging. Becker and colleagues addressed this problem by identifying predictors of disease worsening in the EUSTAR cohort. ARD's social media advisor Dr. Caroline Ospelt talks to Dr. Mike Becker about the res... |
|
| 2020-08-06 |
Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab In this podcast, Dr. Paul Studenic speaks to Dr. Sofia Ramiro and Prof. Robert Landewé both engaged in clinical work in the Zuyderland Medical Center in the south of the Netherlands about their clinical study evaluating systemic glucocorticoids and Il-... |
|
| 2020-04-22 | Statins are some of the most commonly prescribed cholesterol-lowering drugs. They act by inhibiting HMG-CoA reductase, the main enzyme in the synthesis of cholesterol. Earlier studies have shown that statins have an osteoprotective effect: a recently p... |
|
| 2020-03-25 |
A prediction score for individuals at risk to develop rheumatoid arthritis In this podcast recorded at the ACR meeting 2019, Dr. Caroline Ospelt speaks to Prof. Anca Catrina and Dr. Aase Hensvold both of the Division of Rheumatology at the Department of Medicine located at the Karolinska Institute in Stockholm Sweden. Hensvol... |
|
| 2020-03-06 |
Prediction of radiographic progression using synovitis characteristics Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early ... |
|
| 2020-02-18 |
Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone. |
|
| 2020-01-23 |
Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the... |
|